Editas Medicine Inc EDIT
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-02-03 |
| Shares Out. | 167,790,000 |
| Website | editasmedicine.com/ ↗ |
| Phone | 16174019000 |
| Employees | 87 |
| Revenue | $2.8M |
| Gross Profit | $2.8M |
| Net Income | -$25.0M |
| Free Cash Flow | -$141.1M |
| Total Assets | $149.3M |
| Total Liabilities | $144.9M |
| Equity | $4.4M |
About Editas Medicine Inc
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Editas Medicine Inc is a publicly traded company under the ticker symbol EDIT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-07-01)